Results 371 to 380 of about 146,874 (392)

Trastuzumab

2009
Edith A, Perez, Frances M, Palmieri, Shelly M, Brock   +2 more
openaire   +2 more sources

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Nature Medicine, 2023
Fernanda Mosele, Elise Deluche
exaly  

Trastuzumab in CSF

Journal of Clinical Oncology, 2000
Sue Brignoli, Bernhard C. Pestalozzi
openaire   +2 more sources

Trastuzumab Deruxtecan: First Approval

Drugs, 2020
S. Keam
semanticscholar   +1 more source

Trastuzumab--mechanism of action and use in clinical practice.

New England Journal of Medicine, 2007
C. Hudis
semanticscholar   +1 more source

Trastuzumab

2012
Wen Jin Wu, Milos Dokmanovic
openaire   +1 more source

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

The Lancet Oncology, 2019
S. Loi, A. Giobbie-Hurder, A. Gombos, T. Bachelot, R. Hui, G. Curigliano, M. Campone, L. Biganzoli, H. Bonnefoi, G. Jerusalem, R. Bartsch, M. Rabaglio-Poretti, R. Kammler, R. Maibach, M. Smyth, A. Di Leo, M. Colleoni, G. Viale, M. Regan, F. André   +19 more
semanticscholar   +1 more source

Trastuzumab (Herceptin®)

Tijdschrift voor Geneeskunde, 2001
openaire   +1 more source

Trastuzumab: Qui Bono?

JNCI: Journal of the National Cancer Institute, 2013
Ian E. Krop, Harold J. Burstein
openaire   +3 more sources

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Lancet Oncology, The, 2020
Sandra M Swain, Martina Uttenreuther-Fischer, Young-Hyuck Im   +2 more
exaly